Novavax (FRA:NVV1) Cyclically Adjusted PB Ratio: (As of Sep. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NVV1 Novavax Inc FRA:NVV1
49 GF Score
Price €8.45
GF Value €2.71
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Novavax Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Novavax  (FRA:NVV1) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Novavax Cyclically Adjusted PB Ratio Related Terms


Novavax Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Novavax's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax Cyclically Adjusted PB Ratio Chart

Novavax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.17 1.43 1.02 4.78 0.00

Novavax Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:NVV1 vs MAZE, SLBT, AVLN: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Novavax's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novavax Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novavax's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novavax's Cyclically Adjusted PB Ratio falls into.


FRA:NVV1
49GF Score
Novavax Inc FRA:NVV1
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novavax Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Novavax's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Novavax's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-1.004/333.9520*333.9520
=-1.004

Current CPI (Jun. 2026) = 333.9520.

Novavax Quarterly Data

Book Value per Share CPI Adj_Book
201609 3.271 241.428 4.525
201612 -0.388 241.432 -0.537
201703 -1.925 243.801 -2.637
201706 -3.626 244.955 -4.943
201709 -4.011 246.819 -5.427
201712 -5.319 246.524 -7.205
201803 -4.648 249.554 -6.220
201806 -3.934 251.989 -5.214
201809 -5.673 252.439 -7.505
201812 -7.679 251.233 -10.207
201903 -5.677 254.202 -7.458
201906 -6.994 256.143 -9.119
201909 -6.752 256.759 -8.782
201912 -5.175 256.974 -6.725
202003 -0.403 258.115 -0.521
202006 2.677 257.797 3.468
202009 1.436 260.280 1.842
202012 7.266 260.474 9.316
202103 11.786 264.877 14.860
202106 8.334 271.696 10.244
202109 5.200 274.310 6.331
202112 -4.104 278.802 -4.916
202203 0.759 287.504 0.882
202206 -5.046 296.311 -5.687
202209 -7.284 296.808 -8.196
202212 -6.957 296.797 -7.828
202303 -9.694 301.836 -10.725
202306 -7.385 305.109 -8.083
202309 -5.353 307.789 -5.808
202312 -4.712 306.746 -5.130
202403 -5.683 312.332 -6.076
202406 -2.508 314.175 -2.666
202409 -2.962 315.301 -3.137
202412 -3.714 315.605 -3.930
202503 -0.432 319.799 -0.451
202506 0.201 322.561 0.208
202509 -0.822 324.800 -0.845
202512 -0.671 324.054 -0.691
202603 -0.762 330.213 -0.771
202606 -1.004 333.952 -1.004

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Novavax (FRA:NVV1) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of €8.45 is trading 211.8% above its estimated GF Value™ of €2.71. GuruFocus considers Novavax to be Significantly Overvalued.

Key valuation signals for FRA:NVV1:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €2.71 vs. price of €8.45 (211.8% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the FRA:NVV1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
49GF Score

Get the complete analysis for FRA:NVV1

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.45
Price
€2.71
GF Value